Tuesday, October 8, 2013

Biosensors International -NRA-SGX Seminar - Healthcare Part (NRA)

Biosensors International
Current Price S$0.94
52-low S$0.82
52-high S$1.42

Biosensors International Group, Ltd., an investment holding company, engages in the research and development, manufacture, assembly, marketing, distribution, and sale of medical devices for interventional cardiology and critical care procedures worldwide. It operates through three segments: Interventional Cardiology, Critical Care, and Licensing Revenue.
The Interventional Cardiology segment supplies its proprietary drug-eluting stent products, coronary bare-metal stents, accompanying stent delivery balloon catheter systems, angioplasty balloons, and catheters under the BioMatrix Flex, BioMatrix NeoFlex, Axxess, BioFreedom, Gazelle, and Powerline brand names. The Critical Care segment supplies catheter systems and related accessories that are used in surgeries, and intensive care treatment and monitoring procedures. It offers its products under the ACCUTRANS, BIOTRANS, and BIOTRAY brand names. The Licensing Revenue segment engages in the licensing of its proprietary drug-eluting stent technology and intellectual property. The company was founded in 1990 and is headquartered in Singapore.

Recent Financial Overview
Biosensors’s 1Q14 revenue down 11% yoy to US$76.7m mainly due to channel inventory adjustment in China and lower royalty and licensing revenues (-33% yoy). Products’ gross profit margins were down from 81% to 75% in the quarter due to lower gross margin for the company’s IVP product line as a result of its distribution activities in Japan for the Nobori stents, coupled with higher operating expenses, net profit declined by 57% yoy to US$12m (excluding exceptional items).

For the fiscal year ending 31 March 2014, management maintains its previous guidance and continues to expect total revenue to grow by around 15% over FY13. This guidance is driven primarily by continued product revenue growth in the EMEA and APAC regions, as well as the expectation that China sales will recover following the inventory adjustment in Q114. New revenues are also expected from the commercialisation of various new products and the newly acquired business of Spectrum Dynamics. The company expects its aggregate royalty income to improve over its Q114 results.

Source/Extract/Excerpts/来源/转贴/摘录: NRA-Research,
Publish date: 12/09/13

No comments:

Post a Comment

Warren E. Buffett(沃伦•巴菲特)
Be fearful when others are greedy, and be greedy when others are fearful
别人贪婪时我恐惧, 别人恐惧时我贪婪
投资只需学好两门课: 一,是如何给企业估值,二,是如何看待股市波动
吉姆·罗杰斯(Jim Rogers)

乔治·索罗斯(George Soros)



高估期间, 卖对, 不卖也对, 买是错的。
低估期间, 买对, 不买也是对, 卖是错的。

Tan Teng Boo

There’s no such thing as defensive stocks.Every stock can be defensive depending on what price you pay for it and what value you get,
  • Selected Indexes 52 week range

  • Margin of Safety

    Investment Clock

    World's First Interactive Investment Clock